Which patient will benefit most from a platelet inhibitor after a heart operation? The Department of Cardiology of Inselspital, Bern University Hospital, can answer this question with a new test, which has been published in "The Lancet".
Spending less time in hospital, having to take less medication after surgery – both are concerns shared by most patients. In a study published this month, the Department of Cardiology of Inselspital addressed this concern.
In accordance with the principle of weighing benefits and risks, upon which all medical treatments are based, it took an in-depth look at medicinal after-care from the patients’ perspective.
After surgery on the coronary arteries, patients routinely receive platelet-inhibiting drugs for approx. one year. This is intended to prevent heart attacks. These drugs, however, may cause bleeding complications in some patients. Until now, doctors have been unable to find out how high the risk of bleeding was for each person.
Personalised after-care thanks to a simple test
In a multicentric study under the direction of Prof. Marco Valgimigli, from the Department of Cardiology of Inselspital, cardiologists have now developed a simple five-part test: This identifies the individual bleeding risk based on the factors of age, kidney function, haemoglobin level, number of white platelets and previous spontaneous bleedings.
In the case of a high risk, the drugs are prescribed for only approx. three months – because this period of time the patient benefits from the protective effect against heart attack, but has no serious side-effects.
People without an increased risk of bleeding, on the other hand, can take the medicinal coronary prophylaxis for longer because, with good protection, they do not have to worry about bleedings.
Prof. Dr. med. Marco Valgimigli, Senior Physician, Department of Cardiology, Inselspital, Bern University Hospital, +41 31 632 47 14, firstname.lastname@example.org.
Monika Kugemann | Universitätsspital Bern
Spread of deadly eye cancer halted in cells and animals
13.11.2018 | Johns Hopkins Medicine
Breakthrough in understanding how deadly pneumococcus avoids immune defenses
13.11.2018 | University of Liverpool
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly
The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
13.11.2018 | Life Sciences
13.11.2018 | Life Sciences
13.11.2018 | Awards Funding